Univar Solutions B.V.
- Address
- Schouwburgplein 30
Sponsor Overview
Specializations
Wilson’s Disease
Clinical research activity is centered on Wilson’s disease, with interest in the management of copper metabolism disorders and the biochemical markers used to monitor treatment response.
- Hepatic copper accumulation
- Neurologic and systemic manifestations
- Copper balance assessment
The sponsor’s research focus includes therapeutic approaches intended to reduce excess copper and support ongoing disease control in affected patients.
Pharmacokinetics and Pharmacodynamics
Another key area of interest is pharmacokinetic and pharmacodynamic evaluation, particularly the relationship between treatment exposure and biological response in Wilson’s disease.
- Exposure-response relationships
- Drug disposition
- Biomarker-linked response
Research activity is directed toward understanding how treatment levels relate to changes in copper markers and patient-specific response patterns.
Copper Biomarkers
The sponsor shows clear interest in biomarker-based assessment of treatment effects, including measures reflecting circulating and excreted copper burden.
- 24-hour urinary copper excretion
- Serum copper
- Ceruloplasmin
- Non-ceruloplasmin bound copper
This area of research supports clinical evaluation of disease activity and treatment-related changes in copper homeostasis.
Patient Characteristics and Individual Response
Research also extends to the influence of patient characteristics on treatment behavior, including factors that may affect clearance, distribution, and overall therapeutic response.
- Apparent clearance
- Apparent volume of distribution
- Drug potency
This focus reflects interest in how individual clinical features may shape management of Wilson’s disease in routine care.
Oral Chelation Therapy
The therapeutic domain includes trientine dihydrochloride and other chelation-based approaches used to lower excess copper in Wilson’s disease.
- Chelation therapy
- Copper-removal treatment
- Long-term disease management
Clinical interest is concentrated on treatment effects relevant to biochemical control and ongoing monitoring of copper overload.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Pharmacokinetic and Pharmacodynamic Characterization of Trientine Dihydrochloride in Wilson's Disease: A Multicenter, Open-Label, Prospective Study |  Denmark France Germany Poland | Not Recruiting |
Data & Insights
This sponsor works with 1 molecule, of which 1 is not being studied by other sponsors.
This sponsor has worked with 7 sites across their trial portfolio.
Therapeutic Focus
- 1.Nutritional and Metabolic Diseases1 trial211 other sponsors
Partnered Research Centres
7 centres- Address
- Palle Juul-Jensens Boulevard 99, 8200 Aarhus
- Address
- 165 Chemin Du Grand Revoyet, 69310 Pierre Benite
- Address
- 29 Rue Manin, 75019 Paris
- Address
- Aleja Dzieci Polskich 20, 04-730 Warsaw
- Address
- Ul. Jana III Sobieskiego 9, 02-957 Warsaw
- Address
- Im Neuenheimer Feld 410, Neuenheim, 69120 Heidelberg
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Univar Solutions B.V..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.